Landscape overview and modality taxonomy (what “ASO in IBD” means in practice)
Antisense oligonucleotides (ASOs) are short, chemically modified nucleic acids designed to modulate RNA and thereby reduce or alter protein expression. Mechanistically, ASOs include RNase H–dependent “gapmers” (mRNA cleavage), steric-blocking ASOs, and splice-switching oligonucleotides (SSOs); these categories are explicitly discussed in IBD-focused and general ASO reviews 228. Key chemistry toolkits to improve stability/affinity and PK include phosphorothioate linkages, 2′-O-methyl / 2′-O-methoxyethyl (MOE), and locked nucleic acids (LNAs) 148. A 2024 review emphasizes that chemistry choices also shape innate immune activation risk (e.g., TLR-mediated signaling), so sequence and modification choices are part of safety-by-design for nucleic acid drugs 11.
Boundary with RNAi: The competitive “RNA therapeutics” space in IBD often mixes ASOs and siRNA/RNAi programs in pipeline databases, creating category confusion; this matters commercially because delivery technologies, manufacturability, and class risks differ 1.
Delivery strategies for intestinal targets (core differentiator vs systemic immunology drugs)
IBD is unusually suited to local GI delivery, aiming for high mucosal exposure with minimal systemic immunosuppression. Delivery approaches documented across literature and patents include:
- Rectal/topical delivery (enemas) to treat distal UC/proctitis/left-sided disease; this is the most proven ASO delivery mode in IBD clinical trials (e.g., alicaforsen enema) with <0.6% systemic absorption in a PK study 26.
- Oral, colon-targeted delivery using enteric-coated tablets designed for release in the terminal ileum/right colon (prominently in SMAD7/mongersen patent families) 5657.
- Device-enabled site-specific delivery: an ingestible device platform for GI targeting of an SMAD7 inhibitor (including GED-0301/mongersen) is described in a Progenity patent family, with programmable/autonomous release proximate to disease sites 59.
- Colorectal targeting rationale: a delivery commentary argues gut-targeted availability can matter more than systemic bioavailability for enteral oligonucleotides, supporting local intestinal effects while minimizing systemic exposure 10.
Global competitive set: asset-by-asset map (ASO-first, RNA-neighbors as context)
The pipeline dataset used in this work contained ~15 distinct RNA-based entities in IBD (ASO + RNAi), heavily US/EU-weighted and missing China entries in that subset 1. Trial-level evidence, however, is concentrated in alicaforsen and mongersen, with limited structured trial capture for other named assets 2661.
Table 1 — Key ASO/RNA therapeutic programs in IBD identified in retrieved materials
| Program | Modality | Target / pathway | Indication focus | Route(s) | Stage / status in retrieved materials | Trial IDs / key readouts (if available) | Developers / partners |
|---|---|---|---|---|---|---|---|
| Alicaforsen (Camligo; ISIS-2302) | ASO | ICAM-1 (leukocyte trafficking) | UC; pouchitis; oral concept for CD | Rectal enema; oral tablet (tested); also listed IV in pipeline | Multiple Phase II UC studies; Phase III pouchitis negative | NCT02525523 Phase III pouchitis failed co-primary endpoints; no drug-related SAEs reported 26. Phase II UC: 240 mg nightly showed 59% response; durable benefit reported; PK study shows <1% systemic absorption and 58% mucosal healing in 7/12 at week 6 26. Oral tablet disintegration study in healthy volunteers 26. | Atlantic Healthcare; Ionis; (pipeline lists Boehringer Ingelheim historically) 126 |
| Mongersen (GED-0301) | ASO | SMAD7 (restore TGF-β anti-inflammatory signaling) | Crohn’s disease | Oral, enteric/colon targeted (per patents) | Early clinical promise but Phase III failure/suspension | Phase II (EudraCT 2011-002640-27): 65% remission at 160 mg vs 10% placebo (day 15/28 windows) 26. Phase Ib NCT02367183: 12-week arm 67% response, 48% remission, endoscopic response 37% (subset SES-CD>12: 63% ≥25% reduction) 26. Phase III active CD NCT02596893 failed: week 12 remission 22.8% vs 25.0% placebo; endoscopic response 10.1% vs 18.1% placebo 26. Phase III maintenance NCT02641392 suspended for futility 26. | Celgene/BMS and Nogra Pharma (as listed) 26 |
| Cobitolimod (DIMS-0150; Kappaproct) | (Listed as “antisense RNA” in pipeline database; clinically positioned as TLR9 agonist) | TLR9 / NF-κB p65 (RELA) | Left-sided UC | Rectal/topical/oral listed | Phase III discontinued for lack of efficacy | CONCLUDE Induction Study 1 stopped for futility: week 6 clinical remission 4.9% (250 μg), 6.8% (500 mg), 6.7% placebo; well tolerated, no safety differences vs placebo 23. DMC recommended stop after interim analysis (~30% enrolled) 24. | InDex/Flerie; Almirall involved earlier per pipeline 123 |
| SB-012 | ASO | GATA3 | UC | Enema (registry); oral/rectal listed in pipeline | Phase IIa registry exists; no results retrieved | NCT02129439 Phase IIa: 20 patients, Germany; completed 2017; no efficacy results found in retrieved materials 23. | Sterna Biologicals 123 |
| IONIS–Janssen oral GI ASO programs (incl. IONIS-JBI1-2.5Rx) | ASO | Undisclosed | Autoimmune GI / IBD | Oral, locally acting | Partnership active historically; trial identifiers not retrieved | Collaboration announced with nearly $800M in potential milestones across three programs; $10M upfront; Janssen leads global development after Ionis IND-enabling 28. Ionis initiated a Phase 1 study and earned a $5M milestone 29. (No NCT captured in retrieved trial tool outputs.) | Ionis + Janssen/J&J 2829 |
| Other RNA neighbors (context) | siRNA/RNAi; anti-miR | TNFα (CEQ-600), miR-155, miR-146a, MAP4K4, etc. | IBD/CD/UC | Often injectable; some oral claims in pipeline | Preclinical in pipeline dataset; no trials retrieved | No trial IDs/results retrieved 161 | Multiple (Adhera, Regulus/GSK, Ceria, Phio, etc.) 1 |
Important evidence caveat: Multiple tool runs explicitly show that structured clinical trial capture was incomplete for cobitolimod, SB-012, and Ionis-Janssen GI ASO programs (missing NCT/EudraCT identifiers and outcomes in the trial database used) 61. Therefore, this report treats those assets primarily via the specific web/finance sources retrieved.
Recent major updates (past ~12 months) relevant to ASO-in-IBD
- Cobitolimod Phase III discontinuation (value-impacting event): InDex announced discontinuation after Phase III CONCLUDE induction futility; week 6 remission was similar to placebo and there were no safety issues driving the stop 2324.
- China regulatory maturation for oligonucleotides: China’s CDE issued a draft (Sept 2025) technical guideline for chemically synthesized oligonucleotide drugs, detailing CMC expectations and impurity categorization—reducing regulatory ambiguity for ASO developers considering China 64.
- China pipeline signal: China Antibody-B announced NMPA IND approval for SM17, described as a first-in-class therapeutic product for IBD (no modality/target details retrieved beyond this) 62.
- Deals/BD context:
- InDex licensed cobitolimod rights to Viatris Japan (May 2023): $10M upfront, up to $40M milestones, and double-digit royalties; InDex funded development while Viatris Japan handled regulatory/commercialization 27.
- Ionis–Janssen GI oral ASO partnership economics (2016 onwards) remain a key platform validation signal (nearly $800M potential milestones; $10M upfront; $5M Phase 1 start milestone) 2829.
Clinical evidence synthesis and benchmarking vs standard of care (SoC)
What the ASO trials show (and don’t show)
- Alicaforsen (ICAM-1, local enema): In Phase II UC studies, a 240 mg nightly regimen achieved a 59% response (13/22) with durability (reported maintenance of response in follow-up) and 0 discontinuations due to side effects in that study 26. A PK-focused UC study reported 58% mucosal healing (7/12) and <1% systemic absorption, supporting a local-exposure value proposition 26.
However, Phase III pouchitis (NCT02525523) failed its co-primary endpoints (quantitative endpoint rates not provided in the retrieved trial summary) 26. - Mongersen (SMAD7, oral): The clinical story is bifurcated: strong early signals (Phase II 65% remission at 160 mg) 26 and Phase Ib improvements including endoscopic response 26, followed by Phase III failure where remission and endoscopic outcomes were not better than placebo (and in some endpoints numerically worse) 26.
- Cobitolimod (TLR9): Phase III induction showed no efficacy signal and was discontinued for futility, despite being well tolerated 2324.
- SB-012 (GATA3): Existence of a Phase IIa trial is confirmed, but no efficacy/safety results were retrieved 23.
RWE benchmarks that matter for ASO positioning
Because ASO late-stage efficacy in CD/UC is not established in the retrieved materials (and multiple programs failed), the commercially relevant benchmark becomes: can a gut-targeted ASO improve on SoC durability, safety, and/or segment-specific outcomes?
Key RWE signals from the retrieved studies:
- Switching after anti-TNF failure (CD): In German claims, switching outside anti-TNF (to vedolizumab/ustekinumab) outperformed within-class anti-TNF cycling, with lower hazards for prolonged steroid use (HR 1.63 for within-class), second switch (HR 2.44), and discontinuation (HR 1.71) 36. This supports a segmentation thesis: post–anti-TNF failure is heterogeneous and needs better “next mechanism” options.
- Persistence (Japan claims): Ustekinumab showed high persistence (CD 24-month 80.4%, UC 24-month 75.0%), while vedolizumab persistence in CD was lower (24-month 28.6%) 4.
- Hospitalization/infection utilization (US claims): In anti-TNF-experienced CD, ustekinumab vs vedolizumab had similar persistence beyond 52 weeks, but ustekinumab had lower hospitalization rates (all-cause HR 0.73; nonsurgical CD hospitalization HR 0.58; infection hospitalization HR 0.56) 45.
- Perianal CD unmet need: Vedolizumab pooled complete healing 27.6% in predominantly anti-TNF-experienced perianal fistulizing CD 68. Another retrospective cohort linked biologic strategy to 5-year outcomes; anti-TNF at diagnosis reduced abscess recurrence, and ustekinumab at diagnosis was associated with higher fistula closure (HR 3.58) and lower abscess recurrence (HR 0.20) 39.
- Postoperative recurrence (POR): Early anti-TNF prophylaxis (≤4 weeks post-ileocecal resection) reduced POR (aHR 0.61) while later anti-TNF did not; vedolizumab/ustekinumab were not associated with POR reduction in that cohort (limited sample sizes) 40. ENEIDA registry data show POR remains substantial on ustekinumab/vedolizumab (endoscopic POR 42% vs 40% at 12 months) in high-risk, anti-TNF-exposed patients 41.
- Pregnancy and safety constraints: PIANO registry data show biosimilar infliximab pregnancy outcomes comparable to originator infliximab and similar infant developmental milestones at 12 months 66. PIANO also reported no increased risk with vedolizumab or ustekinumab for most maternal/neonatal outcomes; preterm birth differed (UST 0.0% vs VDZ 13.8% in that analysis) 74. Corticosteroids in pregnancy increase risks (e.g., preterm birth OR 1.79, low birth weight OR 1.76) 77, reinforcing the value of effective steroid-sparing maintenance strategies.
RWE-driven patient segmentation opportunities for ASOs (evidence-backed hypotheses)
Given the mixed/negative late-stage ASO efficacy record in retrieved materials, the most defensible investment thesis is segment-first: identify niches where local delivery and mechanism specificity could create measurable value if efficacy is demonstrated.
-
Distal UC / left-sided UC where local delivery is a practical advantage
- Rationale: rectal delivery is mechanistically aligned to disease location; alicaforsen demonstrated minimal systemic absorption (<1%) with mucosal healing signals 26.
- Commercial implication: if a new ASO achieves robust endoscopic endpoints, it could compete in patients needing steroid-sparing options without systemic immunosuppression.
-
Post–anti-TNF failure CD/UC patients where “next mechanism” matters
- Rationale: outside-class switching outperforms within-class cycling in CD claims 36, implying a continued need for differentiated mechanisms (an opening for intracellular/pathway ASOs if they work).
- Guardrail: mongersen’s Phase III failure shows that promising Phase II biology is not sufficient; reproducibility and endpoint rigor are central risks 26.
-
Perianal fistulizing CD as a high-unmet-need phenotype
- Rationale: fistula closure remains limited with non–anti-TNF mechanisms (vedolizumab pooled complete healing 27.6%) 68, and long-term outcomes vary by biologic strategy 39.
- ASO angle: a locally acting (or lesion-targeted) ASO would need a plausible delivery route to perianal lesions (not demonstrated in retrieved ASO data), but the unmet need is clear and investable if delivery innovation emerges.
-
Postoperative recurrence prevention where current options are imperfect
- Rationale: early anti-TNF appears most effective in one real-world cohort 40, while POR rates on ustekinumab/vedolizumab remain substantial in high-risk patients 41.
- ASO angle: a local intestinal, low-systemic-risk maintenance agent could be valuable if it reduces endoscopic POR—no such ASO evidence was retrieved, so this remains a forward-looking diligence topic.
-
Pregnancy / comorbidity-constrained patients prioritizing safety and steroid avoidance
- Rationale: pregnancy safety data support biologics broadly, but steroids drive adverse outcomes 77; maintaining remission is paramount 7074.
- ASO angle: gut-local ASOs with minimal systemic exposure (as demonstrated for alicaforsen enema PK) could become attractive if efficacy is strong enough to replace steroids in flares or maintenance in select settings 26.
Companion diagnostics and biomarkers (where ASOs could differentiate)
A clear, validated predictive biomarker can reshape payer and clinical adoption. Retrieved evidence highlights:
- TREM1 as an anti-TNF response predictor (AUC 0.78 in whole blood; anti-TNF-specific; high post-test probabilities for response/non-response) 5.
- SMAD7 patent families describe polymorphism-tailored targeting and biomarker monitoring concepts (e.g., inflammatory markers; TGF-β pathway readouts) as part of treatment/dosing methods, although this is not proof of clinical utility 5657.
Implication: A next-generation IBD ASO program that pairs mechanism-specific targeting with a clinically usable biomarker strategy could reduce “trial-and-error” sequencing—one reason step-therapy persists when predictive biomarkers are lacking (also noted in payer-focused sequencing analysis) 35.
Commercial outlook (US/EU/China) and market access realities
Market context (from retrieved market sources)
- The inflammatory diseases biologics market was valued at $99.06B (2024), with IBD representing $18.8B (19%); US accounted for 43% of global market value 32.
- The US IBD treatment market is estimated at $13.12B (2024) with biologics >45% of spend; IBD prevalence cited as >3.1M people in the US 33.
- A separate global IBD treatment forecast projects $14.16B (2026) to $17.95B (2035) (CAGR 2.3%) 33. (These sources differ in framing; they should be treated as separate estimates rather than reconciled.)
Payer/HTA pressure: step therapy and value proof
- ACG 2025 UC guidelines explicitly state that payer step therapy should not interfere with clinician-directed access to recommended options 34.
- A managed-care sequencing model (UC) suggests biosimilar infliximab → tofacitinib maximizes net health benefit in that analysis, and that “stepping through” adalimumab as first-line UC was not supported by the model’s rankings 35.
Implication for ASOs: payers will likely demand clear evidence on (1) endoscopic outcomes and durability, and (2) either cost advantage, safety advantage, or biomarker-driven efficiency.
China-specific commercialization considerations
China is transitioning from “nascent” oligonucleotide clinical development to a more structured environment, with new CDE draft guidance for chemically synthesized oligonucleotides 64 and at least one IBD IND (SM17) reported 62. A historical China patent (CN101151035A) documents ICAM-1 antisense (ISIS 2302/alicaforsen) compositions and clinical context, indicating long-standing scientific precedent even if current clinical momentum is limited in retrieved sources 63.
Investment thesis (bull/base/bear) and diligence catalysts
Bull case
- A clinically validated, gut-local ASO achieves robust endoscopic efficacy with minimal systemic exposure (the alicaforsen PK profile shows feasibility of low absorption) 26, enabling differentiation vs systemic immunosuppressants in safety-constrained segments (pregnancy, comorbidity) where steroid avoidance is critical 77.
- Biomarker-enabled targeting reduces cycling inefficiency highlighted by switching outcomes after anti-TNF failure 36 and builds a payer-credible precision narrative (conceptually supported by biomarker work such as TREM1 in anti-TNF selection, though not ASO-specific) 5.
Base case
- ASOs remain niche in IBD due to historical mixed results: mongersen’s Phase II-to-III collapse 26 and cobitolimod’s Phase III futility 23 reinforce development risk. A viable commercial path exists mainly in localized UC or adjunctive/maintenance settings where delivery advantage is strongest and trial endpoints align.
Bear case
- The category fails to produce reproducible late-stage efficacy in CD/UC (as seen with mongersen Phase III and cobitolimod) 2326. With many effective biologics/advanced therapies emerging (e.g., IL-23 program results in CD 46 and TL1A momentum 51), payers and clinicians deprioritize ASOs absent clear superiority.
Priority diligence questions / catalysts (highest impact)
- Confirm missing trial identifiers and full datasets for cobitolimod and SB-012 (NCT/EudraCT, endpoints, subgroup signals), which were not captured in the trial tool outputs 61 despite known discontinuation/topline results for cobitolimod 23.
- Delivery technology validation: evidence that oral/rectal formulations achieve consistent mucosal exposure in the intended anatomical segments (alicaforsen shows one proof point; device-based approaches are patent-described but not clinically validated in retrieved evidence) 2659.
- Reproducibility plan to avoid mongersen-like Phase II/III divergence (population definition, disease location, objective endpoints, placebo response controls) 26.
- China strategy: monitor SM17 clinical entry and how CDE oligonucleotide guidance translates into review timelines and CMC expectations 6264.
- Market access evidence package aligned to guideline and payer realities (step-therapy friction acknowledged in ACG guidance and payer analyses) 3435.
In the retrieved evidence base, IBD ASO development has demonstrated credible local delivery feasibility and early efficacy signals (alicaforsen UC Phase II; mongersen Phase II/Ib) but also high late-stage failure risk (mongersen Phase III; cobitolimod Phase III) 2326. The most investable path is a next-generation, gut-targeted ASO with (1) rigorous endoscopic efficacy, (2) demonstrably low systemic exposure, and (3) a biomarker strategy to win in post-failure segments where RWE shows persistent unmet need and costly therapy cycling 2636.